Redeye updates its estimates following Waystream’s Q2 report last week.
Redeye lowers its estimates and valuation following Vitec’s Q2 2025 report.
Market headwinds worsened by accounting effects Careium delivered soft sales in Q2, with organic gro...
We lower adjusted EBITA by a mere 1% following the Q2 report, which saw adjusted EBITA drop by 22% y...
Q2 results Coor continued the positive trend and delivered better earnings than expected in Q2 while...
Redeye provides its initial take on Lifco’s Q2 2025 report, which came in below our estimates.
Q2 results Organic growth improved and was positive y-o-y, but earnings in service-related units wei...
Redeye comments on Hexatronic’s Q2 report, showing numbers aligning with the preliminary figures.
Plejd rapporterade för andra kvartalet 2025 en nettoomsättning om 210,7 MSEK (146,2), motsvarande en...
- Q2 sales SEK 30m, EBIT -4.7m (vs. ABGSCe 37m and -0.
Redeye comments on Alligator Bioscience's second quarter report 2025.
- Sales -1%, adj. EBIT -2.7m vs. ABGSCe - EBIT lower on higher than expected opex - Recycling contin...
- Q2 sales 8% below our ests. at SEK 202m, for -9% org.
Redeye provides its initial take on Vitec’s Q2 2025 report, which came in considerably below our est...
Redeye comments on Lime’s Q2 report, showing solid underlying numbers despite sales being hurt by so...
Redeye updates its view on Nanologica following the Q2 report.
Incap has guided for net sales to grow by 0-20% for 2025.
Redeye updates its Base Case and forecasts following the Q2 report, showing solid underlying busines...
- Earnings naturally hedged - Potential to generate order intake above the historical average - NTM ...
'25e-'27e adj. EBIT down 8-2% Incident in Spain weighs on near-term momentum Trading at NTM EV/EBITA...